2012

2012 Fourth Quarter - released on 6 February 2013

"In 2012, despite a challenging operating environment, we have maintained core earnings per share on a CER basis, returned over £6.3 billion to shareholders and made outstanding progress to advance potential new medicines across multiple disease areas."


Sir Andrew Witty, CEO

Key highlights

  • Core EPS of 112.7p and returns of £6.3bn to shareholders
  • 2012 dividend of 74p (+6%)
  • Group sales -1%; flat excluding disposals of OTC brands
  • Successful R&D delivery: six new drugs filed since start of 2012

 

2012 Third Quarter - released on 31 October 2012

Key highlights

  • Core EPS of 26.5p
  • Dividend of 18p (+ 6%)
  • Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
  • Continued strong cash generation and returns to shareholders

 

2012 Second Quarter - released on 25 July 2012

"The very significant progress made in our late-stage pipeline provides us with increasing confidence that we have the ability to deliver long-term sustainable sales growth and improving returns to shareholders."

Sir Andrew Witty, CEO

Key highlights

  • Core EPS of 26.4p
  • Dividend of 17p (up 6%)
  • Significant late-stage pipeline delivery

 

2012 First Quarter - released on 25 April 2012

Key highlights

  • Sales growth of +2% CER
  • Further R&D delivery, operational leverage and continued returns to shareholders
  • Core EPS 27.3p (+7%), dividend up 6% to 17p